An interventional study of Contingency Reinforcement and Non-Contingency Reinforcement in Cannabis Use, Major Depressive Disorder and Cognitive Impairment, sponsored by Centre for Addiction and Mental Health. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-02-24.
Sponsored by Centre for Addiction and Mental Health · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 48 studies in Depressive Disorder, Major by Centre for Addiction and Mental Health — 10 open to participants now, 13 under way, none of them phase 3. Depressive Disorder, Major · Centre for Addiction and Mental Health.
Among the 48 studies in Depressive Disorder, Major by Centre for Addiction and Mental Health, this one is the 29th largest by planned enrollment of the 44 interventional ones that give a count, is one of 4 that started in 2021, is one of 36 with no phase, reaches primary completion later than 7 of the 12 other live ones, and was the 35th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →10 of the 48 studies in Depressive Disorder, Major by Centre for Addiction and Mental Health are open now, in 1 country. Recruiting first, the newest first:
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–65
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–50
Centre for Addiction and Mental Health · Sites in Canada
Ages 60+ · Healthy volunteers
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–75 · Healthy volunteers
Centre for Addiction and Mental Health · Sites in Canada
Ages 18–65
By country, each count listing its studies:
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
48 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 3 · Phase 4 1
First in 2001; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 52 is below the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 72 across the 44 interventional studies, 75 across the 4 observational. Of the 34 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Centre for Addiction and Mental Health is the lead sponsor of 339 studies on the registry; 51 are open to participants now.
4 of the studies in Depressive Disorder, Major by Centre for Addiction and Mental Health that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04972136Centre for Addiction and Mental HealthrTMS for Depression in Young Adults With Autism | 2027-01-14 |
| NCT05583747Centre for Addiction and Mental HealthE-field Guided iTBS for Treatment Resistant Depression | 2027-03-31 |
| NCT04935619Centre for Addiction and Mental HealthExtended Effects of Cannabis Abstinence on Clinical Symptoms and Cognition in Depression | 2027-06-30 |
| NCT05142683Centre for Addiction and Mental HealthEffectiveness of an Integrated Care Pathway for Depression: Cluster Randomized Controlled Trial | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 48 studies in Depressive Disorder, Major by Centre for Addiction and Mental Health, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The prevalence of major depressive disorder (MDD) is \~5.0%, and rates of co-occurring SUDs in these patients approach 40-50%. Specifically, rates of co-morbid cannabis use disorder (CUD) in patients with MDD are elevated 2-3 fold compared to 2.9% in the general population, and is associated with poorer treatment outcomes and impaired cognitive and psychosocial functioning in comparison to MDD patients without CUD. Most studies of cannabis use in MDD are cross-sectional in design, and therefore causal relationships are unclear. This study investigates the effects of cannabis abstinence over a 28-day period in patients with MDD with co-occurring CUD using a randomized controlled design, namely contingent reinforcement.
The prevalence of major depressive disorder (MDD) is \~5.0%, and rates of co-occurring SUDs in these patients approach 40-50%. Specifically, rates of co-morbid cannabis use disorder (CUD) in patients with MDD are elevated 2-3 fold compared to 2.9% in the general population, and is associated with poorer treatment outcomes and impaired cognitive and psychosocial functioning in comparison to MDD patients without CUD. To date, most studies of cannabis use in MDD were cross-sectional in design, and therefore causal relationships are unclear. The investigators previous studies in cannabis dependent patients with schizophrenia suggest that extended cannabis abstinence (up to 28 days) using contingent reinforcement is associated with improvements in specific areas of cognition (e.g. verbal learning and memory) and depressive symptoms. A more recent study using an open-label design demonstrated that 28 days of cannabis abstinence improves depressive symptoms and anhedonia in participants (N=11) with co-occurring MDD and CUD.
The investigators propose a controlled cannabis abstinence paradigm in patients with co-morbid MDD and CUD (N=52) to further investigate these findings. Stabilized MDD patients with moderate to severe CUD will be randomly assigned to one of two groups: 1) A contingent reinforcement (CR) intervention (n=26); 2) a non-contingent reinforcement (NCR) intervention (n=26), which will serve as a time and non-abstinence control. In the CR group, subjects achieving biochemically-verified cannabis abstinence at study endpoint (Day 28) will receive a $300 contingent payment; participants in the NCR group will not receive this contingent payment. The primary outcomes are: 1) cannabis abstinence rates at Day 28 in CR versus NCR groups; 2) changes in mood (depressive), anxiety and sleep symptoms over the 28-day assessment period. Secondary outcomes include cognition.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects assigned to the NCR group with self-reported abstinence verified by urinary THC-COOH level \<20 ng/ml will not receive contingency monetary reinforcement at Day 28 of the study.
Behavioral: Non-Contingency Reinforcement
Subjects assigned to the CR group with self-reported abstinence verified by urinary THC-COOH level \<20 ng/ml will receive contingency monetary reinforcement at Day 28 of the study.
Behavioral: Contingency Reinforcement
Subjects will be randomly assigned on a 1:1 ratio to either the Contingency Reinforcement or Non-Contingency Reinforcement Intervention prior to their in-person screening visit.
Subjects will be randomly assigned on a 1:1 ratio to either the Contingency Reinforcement or Non-Contingency Reinforcement Intervention prior to their in-person screening visit.
Changes in Depressive Symptomology from Baseline to Week 4
The Hamilton Depression Rating Scale will be administered to assess severity of depressive symptoms. \[Min score = 0, Max score = 52; Higher scores evince more severe symptomology\]
Time frame: [Time Frame: Weekly (Day 0, Day 7, Day 14, Day 21, Day 28)]
Changes in Anxious Symptomology from Baseline to Week 4
The Beck Anxiety Inventory will be administered to assess severity of anxiety symptoms \[Min score = 0, Max score = 63; Higher scores evince more severe symptomology\].
Time frame: [Time Frame: Weekly (Day 0, Day 7, Day 14, Day 21, Day 28)]
Changes in Sleep Symptomology from Baseline to Week 4
The Pittsburgh Sleep Quality Index will be administered weekly to examine quality of sleep and other sleep disturbances \[Min score = 0, Max score = 21; Higher scores evince more severe symptomology\].
Time frame: [Time Frame: Weekly (Day 0, Day 7, Day 14, Day 21, Day 28)]
Changes in Anhedonia from Baseline to Week 4
The Snaith-Hamilton Pleasure Scale will be administered weekly to measure changes in anhedonia \[Min score = 0, Max score = 14; Higher scores evince more severe symptomology\].
Time frame: [Time Frame: Weekly (Day 0, Day 7, Day 14, Day 21, Day 28)]
Changes in Verbal Learning and Memory
The Hopkins Verbal Learning Test will be administered to investigate this cognitive domain.
Time frame: Day 0 and Day 28
Changes in Attention and Visual Search
The Trail Making Test will be administered to investigate these cognitive domains
Time frame: Day 0 and Day 28
Changes in Working Memory
The Digit Span test will be administered to investigate this cognitive domain.
Time frame: Day 0 and Day 28
Changes in Sustained Attention
The Continuous Performance Test will be administered to investigate this cognitive domain
Time frame: Day 0 and Day 28
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2021 (actual). Primary completion is estimated for Jun 2027, 71 months after the start.
Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 71 months is above that.
Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre for Addiction and Mental Health →